Hideki Noda's '-320°F' turns Sadler's Wells into a biotech fever dream — and leaves its message behind

Hideki Noda's first London show in two decades opened at Sadler's Wells on 3 July 2026 with the unapologetic spectacle of a director who has spent his career refusing to behave. A reimagining of The Tempest transplanted into a near-future biotech dystopia, -320°F drags Shakespeare — and three of his most enduring figures — into a world of cryogenic vaults, sound-conducting bonephones and a corporation that has rebranded the apocalypse as wellness. The Guardian's five-star lead review, published the same day, calls it a "wacky futuristic fantasy" stuffed with "dazzling coups." What the show delivers in formal invention it partially surrenders in thematic clarity, and the trade-off is the story this production wants to tell about itself.

The premise is bracingly strange and, on the evidence of the opening run, theatrically alive. Cleopatra, Faust and the Pied Piper of Hamelin are passengers in a cryonic vessel that has been trapped under frozen earth for 400 years, thawed by an act of corporate charity into a biosphere now run by Noda's Prospero-figure, the philanthropist-cum-villain Doctor Beard. The bones of The Tempest are visible without dominating the scaffold: there is a captive daughter, a captive audience, a captive planet, and a conjurer who can summon both miracles and ruin. The Guardian's review, filed on 3 July 2026, describes the production as "a spectacular vision of villainous biotech" whose formal gambits — actors wired for bone-conducted sound, a stage picture that alternates between glitter and clinical white — repeatedly earn the word "coup." That word, in theatre criticism, is doing precise work: it means a moment where form and meaning align so cleanly that the show briefly transcends its own machinery.

The spectacle, and what it costs

The spectacle is, by most accounts, the point. Noda is a director who has built his reputation on the proposition that Japanese and European theatrical traditions can be fused without either being domesticated — a project visible across his long association with the Saitama Arts Theatre and his decades of work with Kyogen and Shakespeare. -320°F uses bone-conduction technology not as a gimmick but as a dramaturgical tool: whispered asides that the audience hears while the character on stage appears to stay silent, a literal rendering of thought as a different channel of communication. The Guardian's reviewer treats this as the production's signature move, and the technique recurs across the piece's three-hour span.

The cost of that commitment shows in the runtime and the rhetoric. The same review notes that the show "gets bogged down in its earnest message" — a polite way of saying that Noda, having built a machine capable of extraordinary things, cannot resist using it to issue a homily about human warmth. The Doctor Beard character is at once a Faustian tempter and a corporate-villain archetype, the kind of figure who in a Hollywood tentpole would be dispatched with a quip. Here he lingers, and his final-act conversion to the cause of human feeling — which the Guardian flags as a weakness — is the kind of dramaturgical move that earns applause and loses believers.

A director in dialogue with two traditions

Noda's project has never been purely Japanese nor purely European. His career — spanning work at the Royal Shakespeare Company in the 1980s, the founding of the Ryuzanji Company with his wife, the long-running Tokyo collaboration with the Saitama Arts Theatre — has been built on the conviction that the boundaries between Noh, Kabuki, Kyogen and Shakespeare are more porous than national theatre institutions usually admit. -320°F sits squarely inside that programme. The three literary passengers — Cleopatra, Faust, the Pied Piper — are not Western figures imported for prestige; they are the three archetypes Noda needs to populate his future-tense world: desire, knowledge and disappearance. Each is given a stylised body of speech and movement that owes something to Kyogen's economy of gesture and something to Elizabethan verse, and the production makes no effort to hide the seams.

The casting reflects that same deliberate hybridity. The Guardian's review credits a multinational ensemble without naming every performer, but the production's publicity materials — distributed to the press ahead of the 3 July opening — list actors from Japan, Italy and the United Kingdom, with the three archetypal roles split across the languages. It is the kind of casting that, in less confident hands, looks like a marketing decision. Under Noda it reads as an argument: that the future the show is imagining is not owned by any one tradition.

The biotech premise, and what it doesn't do

The premise — that humanity has been sold a future in which cryogenic preservation is rebranded as health optimisation — is the most interesting thing about -320°F, and the most underused. Doctor Beard's corporation is named, in the production's publicity, as a company that has monetised the end of the world. There is a real-world referent here that the show gestures at without ever quite naming: the contemporary wellness industry, the cryonics-adjacent longevity trade, the broader sell of catastrophe as opportunity. Noda's Doctor Beard is recognisable as a particular species of tech philanthropist, the kind who appears on magazine covers between TED talks and Senate hearings.

The production, on the evidence of the opening night, does not have the appetite to follow that thread. Its earnestness — the final-act conversion, the climactic embrace of human feeling as the only salvation from cryogenic numbness — is the show telling the audience what it should feel rather than building the conditions for the audience to feel it. The Guardian's reviewer notes the imbalance explicitly. There is a version of -320°F that trusts its premise and lets Doctor Beard be the monster he is; this version wants him to repent, and the repentance dulls the satire.

What stays with you

What stays, walking out of Sadler's Wells into the early-evening light of Islington, is the bone conduction — the whispered lines that linger in the skull after the actors have left the stage — and the image of a sleeping biosphere being warmed back to life. The production has the conviction to begin with a world already thawed, already sold, and to ask what human feeling is worth when the contract has already been signed. That question is more interesting than the answer the show eventually gives, and the gap between them is the measure of -320°F as a piece of theatre. It is a serious show that has not quite finished thinking itself through, performed with a generosity that almost — but not quite — substitutes for the missing thought.

For a London audience accustomed to the imported polish of Broadway and the West End, Noda's commitment to a hybrid form is itself the news. -320°F runs at Sadler's Wells through mid-July 2026. The bone-conduction sequences alone are worth the ticket. The closing homily is best taken as the price of admission.

This review is based on the opening night of 3 July 2026 and the production's published materials. Monexus framed this as a hybrid-form event — neither a straight Shakespeare nor a contemporary biotech parable — rather than as a revival of The Tempest in modern dress, which is how some early listings positioned it.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://en.wikipedia.org/wiki/Hideki_Noda